# US 7,744,625 B2 · Repair of ruptured membrane by injection of naturally occurring protein in amniotic fluid sac > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,744,625 B2 - Document ID: US7744625B2 - Status: Granted - Kind: B2 - Application number: 10/144,472 - Filed: 2002-05-13 - Published: 2002-09-19 - Granted: 2010-06-29 - Earliest claimed: 2000-04-18 - Inventors: David Berry - Web page: https://patentgrep.com/patent/US7744625B2 ## CPC - A61K 38/38: Albumins - A61B 17/00491: {Surgical glue applicators} - A61B 17/42: Gynaecological or obstetrical instruments or methods {(ligaturing clamps or clips for the umbilical cord A61B17/122; curettage A61B17/320708)} - A61B 17/0057: {Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect (sutures A61B17/04; closing rectum or urethra near body surface A61F2/0009)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) ## Abstract The present invention provides compositions and methods for use in treatment of premature rupture of membrane. The compositions of the invention include a therapeutic amount of an avian thick egg white composition. Preferably, the compositions include the purified thick egg white protein, ovomucin. The methods of the invention involve injecting an effective amount of the compositions into the prematurely ruptured amniotic sac of a patient in order to seal the rupture. ## Claims ### Claim 1 A method of sealing a ruptured amniotic membrane comprising introducing an effective amount of a composition composed of one or more egg white proteins into an amniotic fluid sac of a mammal, wherein the one or more egg white proteins is selected from the group consisting of ovomucin, ovalbumin, avidin, ovoflavoprotein, ovomacroglobulin, ovotransferrin, ovomucoid, ovoinhibitor, and lysozyme. ### Claim 2 (depends on 1) The method of claim 1, wherein the egg white protein is ovomucin. ### Claim 3 (depends on 2) The method of claim 2, wherein the ovomucin is substantially purified. ### Claim 4 (depends on 2) The method of claim 2, wherein the composition comprises ovomucin in the range of 1 to 90 percent by weight. ### Claim 5 (depends on 1) The method of claim 1, wherein the egg white protein is from chicken thick egg white. ### Claim 6 (depends on 1) The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier. ### Claim 7 (depends on 6) The method of claim 6, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, ethanol, and polyol. ### Claim 8 (depends on 7) The method of claim 7, wherein the polyol is selected from the group consisting of glycerol, propylene glycol, and liquid polyethylene glycol. ### Claim 9 (depends on 1) The method of claim 1, wherein the composition is sterile. ### Claim 10 (depends on 1) The method of claim 1, wherein the composition is injected into the amniotic fluid sac. ### Claim 11 (depends on 10) The method of claim 10, wherein the composition is amnioinfused into the amniotic fluid sac. ### Claim 12 (depends on 1) The method of claim 1, wherein the composition further comprises one or more antibiotics, or bacterial inhibiting substances. ### Claim 13 A method of enhancing the integrity of a ruptured amniotic membrane comprising introducing a composition comprising ovomucin into an amniotic fluid sac of a mammal. ### Claim 14 (depends on 13) The method of claim 13, wherein the ovomucin is substantially purified. ### Claim 15 (depends on 13) The method of claim 13, wherein the composition further comprises a pharmaceutically acceptable carrier. ### Claim 16 (depends on 15) The method of claim 15, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, ethanol, and polyol. ### Claim 17 (depends on 16) The method of claim 16, wherein the polyol is selected from the group consisting of glycerol, propylene glycol, and liquid polyethylene glycol. ### Claim 18 (depends on 13) The method of claim 13, wherein the composition comprises ovomucin in the range of 1 to 90 percent by weight. ### Claim 19 (depends on 13) The method of claim 13, wherein the composition is sterile. ### Claim 20 (depends on 13) The method of claim 13, wherein the composition is injected into the amniotic fluid sac. ### Claim 21 (depends on 20) The method of claim 20, wherein the composition is amnioinfused into the amniotic fluid sac. ### Claim 22 (depends on 13) The method of claim 13, wherein the composition further comprises one or more antibiotics, or bacterial inhibiting substances.